BNP Paribas Asset Management
CERE

BNP Paribas Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

BNP Paribas Asset Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-377,329
Closed -$16M – 905
2023
Q4 		$16M Sell
377,329
-182,826
-33% -$5.25M 0.04% 333
2023
Q3 		$12.2M Buy
560,155
+160,287
+40% +$4.01M 0.04% 360
2023
Q2 		$12.7M Sell
399,868
-20,925
-5% -$642K 0.04% 360
2023
Q1 		$10.3M Buy
+420,793
New +$12.4M 0.04% 422

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BNP Paribas Asset Management's CERE Position: Q1 2024 in Review

BNP Paribas Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2024, closing a stake of 377,329 shares — an estimated $16M sold.

BNP Paribas Asset Management first reported a position in CERE in Q1 2023 and held it in 4 quarters. The position peaked at $16M in Q4 2023. 210 funds tracked by Wall St. Rank hold CERE as of Q1 2024.

  • BNP Paribas Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • BNP Paribas Asset Management sold 377,329 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2024, an estimated $16M.
  • BNP Paribas Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2023 and held it in 4 quarters.
  • BNP Paribas Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $16M in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2024.

Based on BNP Paribas Asset Management's 13F filing for Q1 2024, filed 8 May 2024.